+Follow
JYJY96
No personal profile
13
Follow
6
Followers
0
Topic
0
Badge
Posts
Hot
JYJY96
2021-06-18
Yup
Sorry, the original content has been removed
JYJY96
2021-06-18
Wow
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
JYJY96
2021-06-16
Wow
Sorry, the original content has been removed
JYJY96
2021-05-20
I hate motley fool.
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573360859822490","uuid":"3573360859822490","gmtCreate":1610266836508,"gmtModify":1611800360885,"name":"JYJY96","pinyin":"jyjy96","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":13,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.36%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":166791162,"gmtCreate":1624024467656,"gmtModify":1703826890704,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Yup","listText":"Yup","text":"Yup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166791162","repostId":"2144791267","repostType":4,"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166793240,"gmtCreate":1624024449280,"gmtModify":1703826889565,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166793240","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from <b>Johnson & Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from <b>Johnson & Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160375018,"gmtCreate":1623773727434,"gmtModify":1703819110014,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160375018","repostId":"1185254731","repostType":4,"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130169678,"gmtCreate":1621519368394,"gmtModify":1704358978496,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"I hate motley fool. ","listText":"I hate motley fool. ","text":"I hate motley fool.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130169678","repostId":"2136260319","repostType":4,"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":160375018,"gmtCreate":1623773727434,"gmtModify":1703819110014,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160375018","repostId":"1185254731","repostType":4,"repost":{"id":"1185254731","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623764438,"share":"https://ttm.financial/m/news/1185254731?lang=&edition=fundamental","pubTime":"2021-06-15 21:40","market":"us","language":"en","title":"ContextLogic gained as much as 10% a few minutes ago","url":"https://stock-news.laohu8.com/highlight/detail?id=1185254731","media":"Tiger Newspress","summary":"(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for n","content":"<p>(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.</p>\n<p><img src=\"https://static.tigerbbs.com/83f3eeb6c29b019970adceac690d15c3\" tg-width=\"663\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p>\n<p>ContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.</p>\n<p>More than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.</p>\n<p>Alan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”</p>\n<p>Last week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ContextLogic gained as much as 10% a few minutes ago</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContextLogic gained as much as 10% a few minutes ago\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.</p>\n<p><img src=\"https://static.tigerbbs.com/83f3eeb6c29b019970adceac690d15c3\" tg-width=\"663\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p>\n<p>ContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.</p>\n<p>More than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.</p>\n<p>Alan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”</p>\n<p>Last week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185254731","content_text":"(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.\n\nContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.\nMore than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.\nAlan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”\nLast week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130169678,"gmtCreate":1621519368394,"gmtModify":1704358978496,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"I hate motley fool. ","listText":"I hate motley fool. ","text":"I hate motley fool.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130169678","repostId":"2136260319","repostType":4,"repost":{"id":"2136260319","kind":"highlight","pubTimestamp":1621514527,"share":"https://ttm.financial/m/news/2136260319?lang=&edition=fundamental","pubTime":"2021-05-20 20:42","market":"us","language":"en","title":"4 Stocks That Could Be Worth $1 Trillion by 2035","url":"https://stock-news.laohu8.com/highlight/detail?id=2136260319","media":"Motley Fool","summary":"As of today, these innovative companies boast market caps ranging from $81 billion to $198 billion.","content":"<p>Ask any tenured investor and they'll tell you the key to generating significant wealth on Wall Street isn't being right often, but rather being very, <i>very</i> right on a handful of stocks. Having the foresight to identify game-changing companies, and staying firm on your conviction over many years, if not decades, is <a href=\"https://laohu8.com/S/AONE\">one</a> of the easiest ways to gain your financial freedom.</p>\n<p>Though it may be hard to believe, <b>Apple</b> and <b>Amazon</b> were, at <a href=\"https://laohu8.com/S/AONE.U\">one</a> time, part of a very large pack of growth companies struggling to differentiate themselves from their peers. Today, there are countless potential game-changers attempting to stand out from the crowd.</p>\n<p>The big question is: Which stocks have what it takes to eventually enter the $1 trillion valuation club?</p>\n<p>Rather than take the easy road and select companies that are already halfway (or more) to reaching $1 trillion, I decided to look for true innovators with market caps below $200 billion that could grow to a $1 trillion market cap. All four of the following stocks have a real shot at becoming trillion-dollar companies by 2035.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f170884fc838e95b644515ae5882f89e\" tg-width=\"700\" tg-height=\"467\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: Current market cap of $114 billion</h2>\n<p>Singapore-based <b>Sea Limited</b> (NYSE:SE) has all the tools necessary to become a trillion-dollar stock over the next 14 years. It has three operating segments, all of which can play key roles in its ascent to becoming one of the world's largest companies.</p>\n<p>For the time being, Sea is generating most of its earnings before interest, taxes, depreciation, and amortization (EBITDA) from its gaming division. With people stuck in their homes throughout 2020 due to the pandemic, Sea saw its total gaming users grow by 72% to 610.6 million, while the number of paying users rose an even more impressive 120% to 73.1 million.</p>\n<p>Though gaming can be a solid long-term growth driver, it's not the catalyst that'll put Sea over the top. That title belongs to online e-commerce platform Shopee, which is the most popular shopping download in Southeastern Asia. Gross orders last year surged 133% to 2.8 billion, with the gross merchandise value traversing Shopee effectively doubling to $35.4 billion. The scary thing is these figures are just scratching the surface of what Shopee is capable of. Sea is purposely targeting emerging market countries with burgeoning middle classes, which is what'll drive sustainable high double-digit growth.</p>\n<p>Lastly, Sea has a nascent but rapidly growing digital financial services segment. Last year, it tallied more than 23 million paying mobile wallet customers. This operating segment could be surprisingly profitable given how underbanked some of the regions are that Sea operates in.</p>\n<p>With the company on track to more than quadruple its sales by 2024, the sky is the limit.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b7171ad1e94a044e4bf64e685148e98b\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a>: Current market cap of $198 billion</h2>\n<p>Cloud-based customer relationship management (CRM) software juggernaut <b>salesforce.com</b> (NYSE:CRM) is another innovator that has a real shot at hitting $1 trillion in market cap by 2035.</p>\n<p>CRM software is used by consumer-facing businesses to handle simple tasks, such as logging customer information and overseeing product/service issues. It's also leaned on to manage online marketing campaigns and help predict which existing clients might be likeliest to buy new products or services. The retail industry is an obvious beneficiary, but CRM software is finding its way into new industries and sectors as time passes. That's why CRM software remains a double-digit growth trend.</p>\n<p>Salesforce is the unquestioned leader in CRM solutions. IDC's estimate for the first half of 2020 showed that Salesforce controlled 19.8% of global CRM revenue share. By comparison, the next four companies behind it didn't even add up to a 19.8% share. It's going to be extremely difficult for competitors to chip away at what seems like a virtually insurmountable market share lead.</p>\n<p>Furthermore, Salesforce has not been afraid to use acquisitions to broaden its product portfolio or reach new customers. It's currently in the process of acquiring cloud-based enterprise communication platform <b><a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a></b> in a $27.7 billion cash-and-stock deal. Assuming it closes, Salesforce will be able to use Slack's platform as a jumping-off point to cross-sell CRM to small and medium-sized businesses.</p>\n<p>In fiscal 2021, Salesforce generated $21.3 billion in sales. In five years, CEO Marc Benioff sees his company surpassing $50 billion in annual revenue. If this roughly 20% growth rate keeps up, Salesforce should have no issue hitting $1 trillion in 14 years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ec2e9c5a2447c13c9e3c386442802d24\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Airbnb.</span></p>\n<h2>Airbnb: Current market cap of $81 billion</h2>\n<p>The long shot of the group but nevertheless a company with serious growth potential is stay-and-hosting platform <b>Airbnb</b> (NASDAQ:ABNB). Airbnb would have to increase in value by more than 1,100% over the next 14 years to hit a $1 trillion valuation.</p>\n<p>A gain of 1,100%+ probably sounds like a tough task for a company that's nearly a megacap. However, Airbnb is completely revolutionizing the travel and hotel industry, which means its total addressable market is larger than most folks (including those on Wall Street) probably realize.</p>\n<p>The vast majority of investors are probably familiar with Airbnb's hosting platform. The company has courted approximately 4 million hosts worldwide and effectively quintupled bookings between 2016 (52 million) and 2019 (272 million). Yet it's still just getting started. There are more than 130 million households in the U.S. alone and likely more than 1 billion worldwide. Each represents an opportunity to expand its marketplace.</p>\n<p>Best of all, Airbnb isn't just sitting on its laurels and allowing its listing marketplace to do all the work. It has multiple avenues within the travel industry that could prove lucrative. As an example, the introduction of Experiences -- i.e., activities hosted by local experts -- gives the company a new way to generate revenue while also creating unforgettable moments that will bring consumers back to the brand.</p>\n<p>Because Airbnb's potential customer pool is nearly as large as the global population, Wall Street is looking for revenue to more than triple to $10.4 billion in 2024 from $3.4 billion in the pandemic-affected 2020. With consistent growth potential of at least 20%, Airbnb has a real shot at a $1 trillion market cap in 14 years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b7e110d39ab08e59e2378f3f2920fe6e\" tg-width=\"700\" tg-height=\"520\"><span>Image source: Square.</span></p>\n<h2>Square: Current market cap of $92 billion</h2>\n<p>Finally, fintech stock <b>Square</b> (NYSE:SQ) is growing at a lightning-quick pace and has a real chance to break the trillion-dollar barrier by the time 2035 rolls around.</p>\n<p>Square's most mature operating segment is its seller ecosystem. Square provides point-of-sale devices, analytics, loans, and other services to merchants to help them grow. In turn, the seller ecosystem generates most of its revenue from merchant fees via gross payment volume (GPV) traversing its network. Between 2012 and 2019, GPV grew by an average annual rate of 49% to reach north of $106 billion.</p>\n<p>What's worth noting about the seller ecosystem is that it's beginning to attract bigger merchants. In the March-ended quarter, Square generated 61% of its GPV from merchants with at least $125,000 in annualized GPV. That's up nine percentage points from the same quarter in 2019. Bigger merchants mean more gross profit for Square's foundational operating segment.</p>\n<p>But what really has the investment community intrigued is peer-to-peer digital payments platform Cash App. In three years, Cash App's monthly active users more than quintupled to 36 million. Further, gross profit per user, as of the end of 2020, was $41, compared to less than $5 in costs to attract each new user. Not surprisingly, Cash App overtook the seller ecosystem in the first quarter of 2021 as Square's biggest contributor to gross profit.</p>\n<p>Cash App gives the company a multitude of avenues from which to collect revenue. It's pocketing merchant fees, bank transfer revenue, and investing commissions and has generated a boatload of sales from <b>Bitcoin</b> exchange. Square could reasonably double its sales every couple of years through 2035, due in large part to Cash App.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Stocks That Could Be Worth $1 Trillion by 2035</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Stocks That Could Be Worth $1 Trillion by 2035\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-20 20:42 GMT+8 <a href=https://www.fool.com/investing/2021/05/20/4-stocks-that-could-be-worth-1-trillion-by-2035/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ask any tenured investor and they'll tell you the key to generating significant wealth on Wall Street isn't being right often, but rather being very, very right on a handful of stocks. Having the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/20/4-stocks-that-could-be-worth-1-trillion-by-2035/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABNB":"爱彼迎","SE":"Sea Ltd","SQ":"Block","AAPL":"苹果","CRM":"赛富时","AMZN":"亚马逊"},"source_url":"https://www.fool.com/investing/2021/05/20/4-stocks-that-could-be-worth-1-trillion-by-2035/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136260319","content_text":"Ask any tenured investor and they'll tell you the key to generating significant wealth on Wall Street isn't being right often, but rather being very, very right on a handful of stocks. Having the foresight to identify game-changing companies, and staying firm on your conviction over many years, if not decades, is one of the easiest ways to gain your financial freedom.\nThough it may be hard to believe, Apple and Amazon were, at one time, part of a very large pack of growth companies struggling to differentiate themselves from their peers. Today, there are countless potential game-changers attempting to stand out from the crowd.\nThe big question is: Which stocks have what it takes to eventually enter the $1 trillion valuation club?\nRather than take the easy road and select companies that are already halfway (or more) to reaching $1 trillion, I decided to look for true innovators with market caps below $200 billion that could grow to a $1 trillion market cap. All four of the following stocks have a real shot at becoming trillion-dollar companies by 2035.\nImage source: Getty Images.\nSea Limited: Current market cap of $114 billion\nSingapore-based Sea Limited (NYSE:SE) has all the tools necessary to become a trillion-dollar stock over the next 14 years. It has three operating segments, all of which can play key roles in its ascent to becoming one of the world's largest companies.\nFor the time being, Sea is generating most of its earnings before interest, taxes, depreciation, and amortization (EBITDA) from its gaming division. With people stuck in their homes throughout 2020 due to the pandemic, Sea saw its total gaming users grow by 72% to 610.6 million, while the number of paying users rose an even more impressive 120% to 73.1 million.\nThough gaming can be a solid long-term growth driver, it's not the catalyst that'll put Sea over the top. That title belongs to online e-commerce platform Shopee, which is the most popular shopping download in Southeastern Asia. Gross orders last year surged 133% to 2.8 billion, with the gross merchandise value traversing Shopee effectively doubling to $35.4 billion. The scary thing is these figures are just scratching the surface of what Shopee is capable of. Sea is purposely targeting emerging market countries with burgeoning middle classes, which is what'll drive sustainable high double-digit growth.\nLastly, Sea has a nascent but rapidly growing digital financial services segment. Last year, it tallied more than 23 million paying mobile wallet customers. This operating segment could be surprisingly profitable given how underbanked some of the regions are that Sea operates in.\nWith the company on track to more than quadruple its sales by 2024, the sky is the limit.\nImage source: Getty Images.\nSalesforce: Current market cap of $198 billion\nCloud-based customer relationship management (CRM) software juggernaut salesforce.com (NYSE:CRM) is another innovator that has a real shot at hitting $1 trillion in market cap by 2035.\nCRM software is used by consumer-facing businesses to handle simple tasks, such as logging customer information and overseeing product/service issues. It's also leaned on to manage online marketing campaigns and help predict which existing clients might be likeliest to buy new products or services. The retail industry is an obvious beneficiary, but CRM software is finding its way into new industries and sectors as time passes. That's why CRM software remains a double-digit growth trend.\nSalesforce is the unquestioned leader in CRM solutions. IDC's estimate for the first half of 2020 showed that Salesforce controlled 19.8% of global CRM revenue share. By comparison, the next four companies behind it didn't even add up to a 19.8% share. It's going to be extremely difficult for competitors to chip away at what seems like a virtually insurmountable market share lead.\nFurthermore, Salesforce has not been afraid to use acquisitions to broaden its product portfolio or reach new customers. It's currently in the process of acquiring cloud-based enterprise communication platform Slack Technologies in a $27.7 billion cash-and-stock deal. Assuming it closes, Salesforce will be able to use Slack's platform as a jumping-off point to cross-sell CRM to small and medium-sized businesses.\nIn fiscal 2021, Salesforce generated $21.3 billion in sales. In five years, CEO Marc Benioff sees his company surpassing $50 billion in annual revenue. If this roughly 20% growth rate keeps up, Salesforce should have no issue hitting $1 trillion in 14 years.\nImage source: Airbnb.\nAirbnb: Current market cap of $81 billion\nThe long shot of the group but nevertheless a company with serious growth potential is stay-and-hosting platform Airbnb (NASDAQ:ABNB). Airbnb would have to increase in value by more than 1,100% over the next 14 years to hit a $1 trillion valuation.\nA gain of 1,100%+ probably sounds like a tough task for a company that's nearly a megacap. However, Airbnb is completely revolutionizing the travel and hotel industry, which means its total addressable market is larger than most folks (including those on Wall Street) probably realize.\nThe vast majority of investors are probably familiar with Airbnb's hosting platform. The company has courted approximately 4 million hosts worldwide and effectively quintupled bookings between 2016 (52 million) and 2019 (272 million). Yet it's still just getting started. There are more than 130 million households in the U.S. alone and likely more than 1 billion worldwide. Each represents an opportunity to expand its marketplace.\nBest of all, Airbnb isn't just sitting on its laurels and allowing its listing marketplace to do all the work. It has multiple avenues within the travel industry that could prove lucrative. As an example, the introduction of Experiences -- i.e., activities hosted by local experts -- gives the company a new way to generate revenue while also creating unforgettable moments that will bring consumers back to the brand.\nBecause Airbnb's potential customer pool is nearly as large as the global population, Wall Street is looking for revenue to more than triple to $10.4 billion in 2024 from $3.4 billion in the pandemic-affected 2020. With consistent growth potential of at least 20%, Airbnb has a real shot at a $1 trillion market cap in 14 years.\nImage source: Square.\nSquare: Current market cap of $92 billion\nFinally, fintech stock Square (NYSE:SQ) is growing at a lightning-quick pace and has a real chance to break the trillion-dollar barrier by the time 2035 rolls around.\nSquare's most mature operating segment is its seller ecosystem. Square provides point-of-sale devices, analytics, loans, and other services to merchants to help them grow. In turn, the seller ecosystem generates most of its revenue from merchant fees via gross payment volume (GPV) traversing its network. Between 2012 and 2019, GPV grew by an average annual rate of 49% to reach north of $106 billion.\nWhat's worth noting about the seller ecosystem is that it's beginning to attract bigger merchants. In the March-ended quarter, Square generated 61% of its GPV from merchants with at least $125,000 in annualized GPV. That's up nine percentage points from the same quarter in 2019. Bigger merchants mean more gross profit for Square's foundational operating segment.\nBut what really has the investment community intrigued is peer-to-peer digital payments platform Cash App. In three years, Cash App's monthly active users more than quintupled to 36 million. Further, gross profit per user, as of the end of 2020, was $41, compared to less than $5 in costs to attract each new user. Not surprisingly, Cash App overtook the seller ecosystem in the first quarter of 2021 as Square's biggest contributor to gross profit.\nCash App gives the company a multitude of avenues from which to collect revenue. It's pocketing merchant fees, bank transfer revenue, and investing commissions and has generated a boatload of sales from Bitcoin exchange. Square could reasonably double its sales every couple of years through 2035, due in large part to Cash App.","news_type":1},"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166791162,"gmtCreate":1624024467656,"gmtModify":1703826890704,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Yup","listText":"Yup","text":"Yup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166791162","repostId":"2144791267","repostType":4,"repost":{"id":"2144791267","kind":"news","pubTimestamp":1624021620,"share":"https://ttm.financial/m/news/2144791267?lang=&edition=fundamental","pubTime":"2021-06-18 21:07","market":"us","language":"en","title":"Hilton Doubles Down on Las Vegas Growth with Rapidly Expanding Portfolio and Grand Return to the Strip","url":"https://stock-news.laohu8.com/highlight/detail?id=2144791267","media":"Business Wire","summary":"In three years, the global hospitality company has nearly doubled its footprint in the entertainment","content":"<p><i>In three years, the global hospitality company has nearly doubled its footprint in the entertainment capital of the world, poised to support continued recovery of travel with more than 30 hotels in market by the end of 2021</i></p>\n<p><b>LAS VEGAS, Jun 18, 2021</b>--(BUSINESS WIRE)--After revolutionizing the Las Vegas hospitality experience decades ago, Hilton is building on its storied legacy in time for the return to travel by almost doubling its presence in the sought-after global destination over the past three years.</p>\n<p>The company is slated to have more than 30 hotels and over 11,000 rooms across 12 brands in the market by the end of 2021. On the heels of Virgin Hotels Las Vegas, Curio Collection by Hilton’s June opening celebration, and just weeks before the anticipated debut of Conrad Hotels & Resorts, LXR Hotels & Resorts and Hilton Hotels & Resorts at the integrated Resorts World Las Vegas complex, Hilton is making an epic return to this top-tier travel destination, bringing new premium and luxury brands to the Strip.</p>\n<p>\"Hilton helped create the Las Vegas we know today – the entertainment capital of the world grew as we invested in unparalleled hotels, dining, entertainment and design,\" said Hilton President and CEO Chris Nassetta. \"Now we are raising the bar again, offering brands for any style of travel with a renewed focus on premium and luxury hotels. Las Vegas has been an especially bright spot in our global growth strategy, and we are excited to open thousands of rooms there just as people begin traveling again.\"</p>\n<p>Hilton has committed to continue its expansion in the market with a pipeline of seven hotels and nearly 4,000 rooms across five brands, which will increase its footprint by more than 50% by 2023. This adds to the company’s development pipeline of more than 2,570 hotels around the world* and 105 new hotels totalling more than 16,500 rooms opened in the first quarter, along with achieving strong net unit growth of 5.8%.</p>\n<p>Hilton has a storied history in Las Vegas with the former Las Vegas Hilton, once the largest hotel in the world and among the city’s most iconic. The hotel made Hilton the first New York Stock Exchange-listed company to enter the domestic gaming business in 1970 and the first hospitality company to have \"residency\" for top stars as it hosted notable entertainers including Elvis Presley for long runs. With these industry firsts, Hilton helped establish Las Vegas as the prime destination for leisure and business travel it remains today.</p>\n<p>According to a recent survey by Hilton, nearly a quarter of Americans surveyed ranked Las Vegas at the top of their must-visit destinations. Hilton is making those travel wish lists a reality for guests, including more than 115 million Hilton Honors members globally, as it expands its presence in the market. With diverse hotel accommodations, offerings and unique amenities coupled with Hilton’s signature hospitality, the company’s growing Las Vegas properties serve every traveler for every trip occasion, backed by an award-winning guest loyalty program.</p>\n<p><b>What’s new in Las Vegas:</b></p>\n<p>Through a first-of-its-kind partnership, the reimagined and reconceptualized <b>Virgin Hotels Las Vegas, Curio Collection by Hilton </b>offers a relaxed, whimsical design and more than 1,500 chambers and suites providing a distinctly home-away-from-home personalized getaway. The resort oasis also features an exclusive spa, a five-acre pool complex including VIP-style cabanas and daybeds along with a beach club, vibrant live entertainment venues, a state-of-the-art casino and 110,000 square feet of meeting and event space. Guests can also indulge in a world-class portfolio of 12 restaurants and bars including Mediterranean dishes at Chef Todd English’s Olives, Japanese cuisine at Chef Nobu Matsuhisa’s Nobu and hand-crafted cocktails at The Shag Room.</p>\n<p>Additionally, through a historic partnership between Hilton and Genting Group, <b>Resorts World Las Vegas </b>is set to open June 24 and marks the largest multi-brand deal in Hilton’s history. The $4.3 billion development integrates the largest Conrad Hotels & Resorts property in the world, <a href=\"https://laohu8.com/S/AONE\">one</a> of the first LXR Hotels & Resorts locations in the U.S. and a marquee Hilton Hotels & Resorts hotel, each offering its own dedicated entrance, lobby and distinct collection of accommodations. In addition, Resorts World Las Vegas is poised to be Hilton’s largest property globally, with 3,500 guest rooms and suites. With its opening, Conrad and LXR will join Waldorf Astoria in the market to make Las Vegas the only U.S. destination housing all three of Hilton’s luxury brands. The first ground-up resort development on the Las Vegas Strip in more than a decade, the property is also conveniently near the Las Vegas Convention Center.</p>\n<p>Guests staying at any of the three hotels can enjoy premium amenities across the Resorts World Las Vegas campus including more than 40 food and beverage outlets, seven unique pool experiences, an expansive next-generation casino floor, over 250,000 square feet of flexible meeting space and a 5,000-capacity theatre that will be home to can’t-miss performances by Celine Dion, Carrie Underwood, Katy Perry and Luke Bryan.</p>\n<p>Other updates and recent additions to Hilton’s Las Vegas portfolio include:</p>\n<ul>\n <li><b>Waldorf Astoria Las Vegas </b>– Hilton’s first and most iconic luxury brand brought a new spirit to the Strip in 2018 and continues to deliver graceful service nestled in an oasis of modern luxury and intrigue. The hotel’s award-winning spa, inviting eighth- floor pool deck and gourmet dining experiences, including high tea in the stylish Tea Lounge or craft cocktails with splendid views of the Strip at Skybar, provide unexpected moments for all who visit. An upcoming transformation of the hotel’s guestrooms, meeting space and lobby experience boasts a sleek, contemporary design with floor-to-ceiling windows that frame spectacular views of Las Vegas Boulevard and the surrounding desert landscape.</li>\n</ul>\n<ul>\n <li><b>Hampton by Hilton Las Vegas Strip South </b>– The property opened on the south end of the Strip in December 2020 and provides easy access to the city for travelers seeking value-driven, best-in-class accommodations. The colorful hotel offers friendly service, an outdoor pool, fitness center and lounge area, along with spacious rooms, complimentary breakfast and free Wi-Fi.</li>\n</ul>\n<ul>\n <li><b>Hampton Inn & Suites by Hilton Las Vegas Convention Center / Home2 Suites by Hilton Las Vegas Convention Center </b>– The dual-branded hotel opened in August 2020 and is conveniently located across from the Las Vegas Convention Center. The property features a bespoke \"Hello LoVe\" design that celebrates the vibrant, innovative spirit of Las Vegas. Both brands offer complimentary breakfast and free Wi-Fi, and Home2 Suites is pet-friendly, providing an accessible extended stay option for the whole family, pets included.</li>\n</ul>\n<p>Hilton’s new and upcoming properties will make it easier than ever for Hilton Honors members to earn and redeem Points during their next trip to Las Vegas. Members who book directly through preferred Hilton channels receive exclusive benefits, discounts and rewards, access to industry-leading contactless technology through the Hilton Honors app, and hundreds of ways to earn and redeem Points on free nights, premium merchandise, charitable contributions and unique experiences.</p>\n<p>For more information, visit https://newsroom.hilton.com/las-vegas.</p>\n<p><b>About Hilton</b></p>\n<p>Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,500 properties and more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> million rooms, in 119 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2020 World’s Best Workplaces list, and was named the 2020 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the more than 115 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors mobile app, guests can book their stay, select their room, check in, unlock their door with Digital Key and check out, all from their smartphone. Visit newsroom.hilton.com for more information, and connect with Hilton on <a href=\"https://laohu8.com/S/FB\">Facebook</a>, <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>, LinkedIn, Instagram and YouTube.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hilton Doubles Down on Las Vegas Growth with Rapidly Expanding Portfolio and Grand Return to the Strip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHilton Doubles Down on Las Vegas Growth with Rapidly Expanding Portfolio and Grand Return to the Strip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:07 GMT+8 <a href=https://finance.yahoo.com/news/hilton-doubles-down-las-vegas-130700720.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In three years, the global hospitality company has nearly doubled its footprint in the entertainment capital of the world, poised to support continued recovery of travel with more than 30 hotels in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hilton-doubles-down-las-vegas-130700720.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLT":"希尔顿酒店"},"source_url":"https://finance.yahoo.com/news/hilton-doubles-down-las-vegas-130700720.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144791267","content_text":"In three years, the global hospitality company has nearly doubled its footprint in the entertainment capital of the world, poised to support continued recovery of travel with more than 30 hotels in market by the end of 2021\nLAS VEGAS, Jun 18, 2021--(BUSINESS WIRE)--After revolutionizing the Las Vegas hospitality experience decades ago, Hilton is building on its storied legacy in time for the return to travel by almost doubling its presence in the sought-after global destination over the past three years.\nThe company is slated to have more than 30 hotels and over 11,000 rooms across 12 brands in the market by the end of 2021. On the heels of Virgin Hotels Las Vegas, Curio Collection by Hilton’s June opening celebration, and just weeks before the anticipated debut of Conrad Hotels & Resorts, LXR Hotels & Resorts and Hilton Hotels & Resorts at the integrated Resorts World Las Vegas complex, Hilton is making an epic return to this top-tier travel destination, bringing new premium and luxury brands to the Strip.\n\"Hilton helped create the Las Vegas we know today – the entertainment capital of the world grew as we invested in unparalleled hotels, dining, entertainment and design,\" said Hilton President and CEO Chris Nassetta. \"Now we are raising the bar again, offering brands for any style of travel with a renewed focus on premium and luxury hotels. Las Vegas has been an especially bright spot in our global growth strategy, and we are excited to open thousands of rooms there just as people begin traveling again.\"\nHilton has committed to continue its expansion in the market with a pipeline of seven hotels and nearly 4,000 rooms across five brands, which will increase its footprint by more than 50% by 2023. This adds to the company’s development pipeline of more than 2,570 hotels around the world* and 105 new hotels totalling more than 16,500 rooms opened in the first quarter, along with achieving strong net unit growth of 5.8%.\nHilton has a storied history in Las Vegas with the former Las Vegas Hilton, once the largest hotel in the world and among the city’s most iconic. The hotel made Hilton the first New York Stock Exchange-listed company to enter the domestic gaming business in 1970 and the first hospitality company to have \"residency\" for top stars as it hosted notable entertainers including Elvis Presley for long runs. With these industry firsts, Hilton helped establish Las Vegas as the prime destination for leisure and business travel it remains today.\nAccording to a recent survey by Hilton, nearly a quarter of Americans surveyed ranked Las Vegas at the top of their must-visit destinations. Hilton is making those travel wish lists a reality for guests, including more than 115 million Hilton Honors members globally, as it expands its presence in the market. With diverse hotel accommodations, offerings and unique amenities coupled with Hilton’s signature hospitality, the company’s growing Las Vegas properties serve every traveler for every trip occasion, backed by an award-winning guest loyalty program.\nWhat’s new in Las Vegas:\nThrough a first-of-its-kind partnership, the reimagined and reconceptualized Virgin Hotels Las Vegas, Curio Collection by Hilton offers a relaxed, whimsical design and more than 1,500 chambers and suites providing a distinctly home-away-from-home personalized getaway. The resort oasis also features an exclusive spa, a five-acre pool complex including VIP-style cabanas and daybeds along with a beach club, vibrant live entertainment venues, a state-of-the-art casino and 110,000 square feet of meeting and event space. Guests can also indulge in a world-class portfolio of 12 restaurants and bars including Mediterranean dishes at Chef Todd English’s Olives, Japanese cuisine at Chef Nobu Matsuhisa’s Nobu and hand-crafted cocktails at The Shag Room.\nAdditionally, through a historic partnership between Hilton and Genting Group, Resorts World Las Vegas is set to open June 24 and marks the largest multi-brand deal in Hilton’s history. The $4.3 billion development integrates the largest Conrad Hotels & Resorts property in the world, one of the first LXR Hotels & Resorts locations in the U.S. and a marquee Hilton Hotels & Resorts hotel, each offering its own dedicated entrance, lobby and distinct collection of accommodations. In addition, Resorts World Las Vegas is poised to be Hilton’s largest property globally, with 3,500 guest rooms and suites. With its opening, Conrad and LXR will join Waldorf Astoria in the market to make Las Vegas the only U.S. destination housing all three of Hilton’s luxury brands. The first ground-up resort development on the Las Vegas Strip in more than a decade, the property is also conveniently near the Las Vegas Convention Center.\nGuests staying at any of the three hotels can enjoy premium amenities across the Resorts World Las Vegas campus including more than 40 food and beverage outlets, seven unique pool experiences, an expansive next-generation casino floor, over 250,000 square feet of flexible meeting space and a 5,000-capacity theatre that will be home to can’t-miss performances by Celine Dion, Carrie Underwood, Katy Perry and Luke Bryan.\nOther updates and recent additions to Hilton’s Las Vegas portfolio include:\n\nWaldorf Astoria Las Vegas – Hilton’s first and most iconic luxury brand brought a new spirit to the Strip in 2018 and continues to deliver graceful service nestled in an oasis of modern luxury and intrigue. The hotel’s award-winning spa, inviting eighth- floor pool deck and gourmet dining experiences, including high tea in the stylish Tea Lounge or craft cocktails with splendid views of the Strip at Skybar, provide unexpected moments for all who visit. An upcoming transformation of the hotel’s guestrooms, meeting space and lobby experience boasts a sleek, contemporary design with floor-to-ceiling windows that frame spectacular views of Las Vegas Boulevard and the surrounding desert landscape.\n\n\nHampton by Hilton Las Vegas Strip South – The property opened on the south end of the Strip in December 2020 and provides easy access to the city for travelers seeking value-driven, best-in-class accommodations. The colorful hotel offers friendly service, an outdoor pool, fitness center and lounge area, along with spacious rooms, complimentary breakfast and free Wi-Fi.\n\n\nHampton Inn & Suites by Hilton Las Vegas Convention Center / Home2 Suites by Hilton Las Vegas Convention Center – The dual-branded hotel opened in August 2020 and is conveniently located across from the Las Vegas Convention Center. The property features a bespoke \"Hello LoVe\" design that celebrates the vibrant, innovative spirit of Las Vegas. Both brands offer complimentary breakfast and free Wi-Fi, and Home2 Suites is pet-friendly, providing an accessible extended stay option for the whole family, pets included.\n\nHilton’s new and upcoming properties will make it easier than ever for Hilton Honors members to earn and redeem Points during their next trip to Las Vegas. Members who book directly through preferred Hilton channels receive exclusive benefits, discounts and rewards, access to industry-leading contactless technology through the Hilton Honors app, and hundreds of ways to earn and redeem Points on free nights, premium merchandise, charitable contributions and unique experiences.\nFor more information, visit https://newsroom.hilton.com/las-vegas.\nAbout Hilton\nHilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,500 properties and more than one million rooms, in 119 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2020 World’s Best Workplaces list, and was named the 2020 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the more than 115 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors mobile app, guests can book their stay, select their room, check in, unlock their door with Digital Key and check out, all from their smartphone. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook, Twitter, LinkedIn, Instagram and YouTube.","news_type":1},"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166793240,"gmtCreate":1624024449280,"gmtModify":1703826889565,"author":{"id":"3573360859822490","authorId":"3573360859822490","name":"JYJY96","avatar":"https://static.tigerbbs.com/6173055e5493fb0b0baeb4ad51e3775d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573360859822490","authorIdStr":"3573360859822490"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166793240","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from <b>Johnson & Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from <b>Johnson & Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
